# IDXX — IDEXX Laboratories · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IDXX  
**Sources:** 27  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-idxx-idexx-laboratories-catalysts-narrative-risks-5939

---

# IDEXX Laboratories (IDXX) — Research Snapshot as of 2026-10-03

**Listing / classification:** NASDAQ (S&P 500 member), filed under *animal_health*. [[22]](https://ir.idexx.com/company-information)[[23]](https://finance.yahoo.com/quote/IDXX/)[[24]](https://stockanalysis.com/stocks/idxx/)

---

## Key Recent Catalysts (July–October 2026)

**1. Q2 2026 earnings beat (reported August 4, 2026).** IDEXX reported diluted EPS of $4.27 (up ~18% year-over-year, beating the Zacks Consensus estimate by ~8.1%) and revenue of $1.22 billion (up ~10%), exceeding consensus on both lines. Companion Animal Group (CAG) Diagnostics recurring revenues rose 11% as reported / 10% organically. [[10]](https://finance.yahoo.com/markets/stocks/articles/idexx-idxx-down-7-8-153015551.html)[[18]](https://www.marketbeat.com/stocks/NASDAQ/IDXX/earnings/)[[23]](https://finance.yahoo.com/quote/IDXX/)[[24]](https://stockanalysis.com/stocks/idxx/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-idxx-idexx-laboratories-catalysts-narrative-risks-5939 (free to sign up)._
